Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

February 14, 2024

Study Completion Date

February 28, 2024

Conditions

Polycystic Ovary Syndrome

Interventions

DRUG

Salsalate

Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid

OTHER

Placebo

Appears identical to experimental drug

Trial Locations (1)

Frank González, Chicago

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Illinois at Chicago

OTHER

NCT03229408 - Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction | Biotech Hunter | Biotech Hunter